SCHEMBL4944528

SCHEMBL4944528

OCc1ccc(Sc2ccncc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDAH1 O94760 1/20 0.61
NOS1 P29475 1/20 0.61
PRKCI P41743 1/20 0.46
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
MIF P14174 1/20 0.42
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
BRAF P15056 1/20 0.40
FYN P06241 1/20 0.40
NR1H2 P55055 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10887327 0.86 TSHR (0.48) NOS1ALDH1A1CYP3A4MKNK1MKNK2
SCHEMBL1439245 0.79 MKNK1 (0.61) PRKCICYP3A4MKNK1MKNK2CYP11B1
SCHEMBL4945787 0.79 MIF (0.61) DDAH1NOS1PRKCIALDH1A1CYP1A2
SCHEMBL4938425 0.79 PRKCI (0.61) DDAH1NOS1PRKCIALDH1A1CYP1A2
Pyridine 4-Methanol SCHEMBL102606 0.78
SCHEMBL144087 0.78 DDAH1 (1.00) DDAH1NOS1ALDH1A1CYP1A2CYP3A4
SCHEMBL5761245 0.77 TSHR (0.59) ALDH1A1NR1H2TSHRTOP2ATOP2B
Pyridine 4-Methanol SCHEMBL26112701 0.76
Pyridine 4-Methanol SCHEMBL4445081 0.76
Pyridine 4-Methanol SCHEMBL28294333 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293684-A1 Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors MERCK SHARP & DOHME CORP. 2008-11-27 US disclosed
CN-1993326-A Heterocyclic acetophenone potentiators of metabotropic glutamate receptors MERCK & CO INC (US) 2007-07-04 CN disclosed
EP-1773774-A2 HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS Merck & Co., Inc. (US) 2007-04-18 EP disclosed
WO-2006014918-A2 HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK & CO., INC. (US) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293684-A1 Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors GRM2, GRM1, GRIK2 DDAH1 1668/4885NOS1 3147/4885PRKCI 3451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.